Renal Protection at a Metabolic Cost: A Systematic Review and Meta‐Analysis of Perioperative Use of Sodium–Glucose Cotransporter 2 Inhibitors
The use of perioperative SGLT2 inhibitors poses a clinical paradox between significant renoprotection and survival advantages and a latent risk of ketoacidosis concealed by considerable heterogeneity. While metabolic monitoring is essential, current surgeries requiring more prolonged withholding may need to weigh metabolic risk against the drug's significant benefit in reducing acute kidney injury and mortality.
Authors
- Abdalhakim R. M. Shubietah (ORCID: https://orcid.org/0000-0002-8300-0262)
- AlMothana Manasrah (ORCID: https://orcid.org/0009-0001-6266-4991)
- Nourhan N Elguindy
- Mohammad Bazzazeh
- Ahmed Elbataa (ORCID: https://orcid.org/0009-0009-7065-381X)
- Elsayed Balbaa (ORCID: https://orcid.org/0009-0008-8005-7029)
- M S Elgendy
- Ahmed Ibrahim
- Ameer Awashra
- Ahmed Mansour
- Abdelhamid Ben‐Selma
- Ahmed Farid Gadelmawla
- Ahmed Sobhy
Institutions
- Kafrelsheikh University (EG)
- Cairo University (EG)
- Al-Azhar University (EG)
- Tanta University (EG)
- United Health Services (US)
- Advocate Illinois Masonic Medical Center (US)
- Menoufia University (EG)
- Alexandria University (EG)
Publication Details
- Journal
- Endocrinology Diabetes & Metabolism
- Published
- 2026-02-21
- DOI
- https://doi.org/10.1002/edm2.70180
- Primary Topic
- Potassium and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00